Advances in the management of diabetic peripheral neuropathy.
about
The Effect of Capsaicin on Salivary Gland DysfunctionCentral nervous system involvement in diabetic neuropathy.Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.Jinmaitong decreases sciatic nerve DNA oxidative damage and apoptosis in a streptozotocin-induced diabetic rat model.Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United KingdomMitochondrion-Permeable Antioxidants to Treat ROS-Burst-Mediated Acute Diseases.Therapeutic Potential of Dioscorea Extract (DA-9801) in Comparison with Alpha Lipoic Acid on the Peripheral Nerves in Experimental DiabetesPulsed radiofrequency attenuates diabetic neuropathic pain and suppresses formalin-evoked spinal glutamate release in ratsDiabetic painful and insensate neuropathy: pathogenesis and potential treatments.Urinary methylmalonic acid as an indicator of early vitamin B12 deficiency and its role in polyneuropathy in type 2 diabetes.Long-term pain in cats: how much do we know about this important welfare issue?Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators.Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea.A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.Magnetic resonance imaging of the central nervous system in diabetic neuropathy.Recent advances in the management of diabetic distal symmetrical polyneuropathyEvaluating the Measurement Properties of the Self-Assessment of Treatment Version II, Follow-Up Version, in Patients with Painful Diabetic Peripheral Neuropathy.Capsaicin and dihydrocapsaicin determination in chili pepper genotypes using ultra-fast liquid chromatography.Glycolytic metabolite methylglyoxal inhibits cold and menthol activation of the transient receptor potential melastatin type 8 channel.Amelioration of Diabetes and Painful Diabetic Neuropathy by Punica granatum L. Extract and Its Spray Dried Biopolymeric Dispersions.Angiogenin gene polymorphism: A risk factor for diabetic peripheral neuropathy in the northern Chinese Han population.Impaired noradrenaline homeostasis in rats with painful diabetic neuropathy as a target of duloxetine analgesia.Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain.Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study.Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.The neuroprotective benefit from pioglitazone (PIO) addition on the alpha lipoic acid (ALA)-based treatment in experimental diabetic rats.Monochromatic Infrared Photo Energy in Diabetic Peripheral Neuropathy
P2860
Q26747031-152DE02F-1D6D-415D-85AB-62FCFBE1364FQ33930708-66B9DFFB-9FB4-4511-B86D-706C6D6B1502Q34153575-A94C43AC-79D9-43EB-B707-7B92B2F982BDQ35576767-74134C23-D21F-4F8B-A5F7-8111EAA626E4Q35870512-0A8A35F7-8EA9-4166-8271-3355453E5F6BQ36032032-00241938-842F-4D41-89A6-4749B891B147Q36329020-2BEAC678-346E-4C81-AAB9-4E827D8F6AD6Q36825657-945E06BE-E1DB-4AD4-890D-4CEE8FFD462BQ37513484-BF8A228E-1133-4109-9800-288102522158Q37605348-A10A6D81-72CF-4D3C-929A-B55FA39654F1Q37639716-D8B730CF-11D8-4B66-ABC5-1B8F0C85FC93Q37701027-DFFE996E-698B-4F52-8B10-C649627233CCQ37879583-6B9141FB-2F0F-4A55-92BA-6DEF04CE30DFQ38004085-14D9474F-E9C7-48DA-871B-6421644442CFQ38020236-9D394652-9058-4A17-AF13-E397C39E83E2Q38111241-B2700373-DFE6-40B3-9E2C-BB2F35F60BFCQ38213043-41DD8856-A2C6-41B9-A700-4ABFA56C03CEQ38964662-174CD6B9-342F-425A-B17A-EA8B6471C6C8Q39544436-1D8F9AC6-35A2-44E6-9016-C57FE853796CQ40250061-1234588A-D28D-439F-96FC-F92773218B9DQ40734719-EDF8B939-16AA-4A11-B708-4C2973D575BEQ42084622-138369BC-4475-4BC2-8504-7F5E64FF9450Q42099980-A91C68A4-361A-440E-83CE-095B7B3E13F1Q46743002-7FC94F60-73E7-4490-B5D0-425BB78F327DQ48308914-250FC78F-A68C-40EE-A58B-A50D651373DFQ48850110-64679CBA-6CE5-48E8-B59A-D99BB558DDE3Q51017318-11D36E26-FC51-42C4-AC3F-0342D410E6A9Q53295371-8879C52B-4A2D-4FBF-9359-5D1CC4DFF93FQ58690868-D9AEE00A-6BB5-486E-9BD6-E367FE2457F4
P2860
Advances in the management of diabetic peripheral neuropathy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Advances in the management of diabetic peripheral neuropathy.
@en
Advances in the management of diabetic peripheral neuropathy.
@nl
type
label
Advances in the management of diabetic peripheral neuropathy.
@en
Advances in the management of diabetic peripheral neuropathy.
@nl
prefLabel
Advances in the management of diabetic peripheral neuropathy.
@en
Advances in the management of diabetic peripheral neuropathy.
@nl
P1476
Advances in the management of diabetic peripheral neuropathy.
@en
P304
P356
10.1097/SPC.0B013E32832B7DF5
P577
2009-06-01T00:00:00Z